Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus panitumumab in first-line KRAS/BRAF wild-type metastatic colorectal cancer
2009-014556-29Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, irinotecan, oxaliplatin, fluorouracil and levoleucovorin in metastatic colorectal adenocarcinoma (mCRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Response rate. Started Feb 2010; status: completed.
02
Drugs
panitumumabirinotecanoxaliplatinfluorouracillevoleucovorin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-014556-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014556-29.